CIM
SUPN icon

Contravisory Investment Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Contravisory Investment Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,981
Closed -$309K – 436
2026
Q1 		$309K Hold
5,981
– – 0.06% 172
2025
Q4 		$297K Sell
5,981
-222
-4% -$10.8K 0.06% 191
2025
Q3 		$296K Buy
+6,203
New +$250K 0.06% 206

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Contravisory Investment Management's SUPN Position: Q2 2026 in Review

Contravisory Investment Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2026, closing a stake of 5,981 shares — an estimated $309K sold.

Contravisory Investment Management first reported a position in SUPN in Q3 2025 and held it in 3 quarters. The position peaked at $309K in Q1 2026. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Contravisory Investment Management reported no remaining Supernus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Contravisory Investment Management sold 5,981 Supernus Pharmaceuticals shares in Q2 2026, an estimated $309K.
  • Contravisory Investment Management first reported a position in Supernus Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Contravisory Investment Management's Supernus Pharmaceuticals position peaked at $309K in Q1 2026.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Contravisory Investment Management's 13F filing for Q2 2026, filed 9 Jul 2026.